Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IBI188 + decitabine
- Development stage
- Phase 2
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**IBI188 + decitabine** is an experimental combination therapy under investigation for the treatment of acute myeloid leukemia (AML). **IBI188** is a monoclonal antibody targeting CD47, functioning as a "don't eat me" signal inhibitor to promote macrophage-mediated phagocytosis of cancer cells. **Decitabine** is a DNA methyltransferase inhibitor (a hypomethylating agent) that induces DNA hypomethylation and cell differentiation/apoptosis. The combination aims to leverage the immunotherapeutic effects of IBI188 with the epigenetic modulatory and cytotoxic properties of decitabine. This combination is in clinical trials primarily for AML, particularly in patients ineligible for intensive chemotherapy.
02
Targets
CD47 (Cluster of Differentiation 47)DNMT1 (DNA (cytosine-5)-methyltransferase 1)
Beyond the preview
Go deeper on IBI188 + decitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IBI188 + decitabine.